$66.65
1.322.02%
In chiusura: -
$67.65
1.001.50%
After hour: 5:29 PM EDT
Comments
Loading...
Stime degli utili, EPS e fatturato
Halozyme Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Data degli utili
ott 30
Stima EPS
$1.580
Stima dei ricavi trimestrali
$338.86M
Ricavi annuali
(a partire da giu 30)
(a partire da giu 30)
$1.18B
Analizza lo storico degli utili di Halozyme Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
HALO | Halozyme Therapeutics | $1.27 | $1.58 | — | — | $290.08M | $338.86M | — | — | 10/30/2025 | |
HALO | Halozyme Therapeutics | $0.91 | $1.20 | $1.54 | 28.33% | $231.35M | $286.00M | $325.72M | 13.89% | 08/05/2025 | |
HALO | Halozyme Therapeutics | $0.79 | $0.94 | $1.11 | 18.09% | $195.88M | $230.18M | $264.86M | 15.07% | 05/06/2025 | |
HALO | Halozyme Therapeutics | $0.82 | $1.16 | $1.26 | 8.62% | $230.04M | $285.74M | $298.01M | 4.29% | 02/18/2025 | |
HALO | Halozyme Therapeutics | $0.75 | $0.98 | $1.27 | 29.59% | $216.03M | $251.06M | $290.08M | 15.54% | 10/31/2024 | |
HALO | Halozyme Therapeutics | $0.74 | $0.78 | $0.91 | 16.67% | $221.04M | $208.94M | $231.35M | 10.73% | 08/06/2024 | |
HALO | Halozyme Therapeutics | $0.47 | $0.69 | $0.79 | 14.49% | $162.14M | $199.78M | $195.88M | -1.95% | 05/07/2024 | |
HALO | Halozyme Therapeutics | $0.48 | $0.83 | $0.82 | -1.20% | $181.50M | $233.19M | $230.04M | -1.35% | 02/20/2024 | |
HALO | Halozyme Therapeutics | $0.74 | $0.73 | $0.75 | 2.74% | $208.98M | $222.63M | $216.03M | -2.96% | 11/06/2023 | |
HALO | Halozyme Therapeutics | $0.53 | $0.63 | $0.74 | 17.46% | $152.37M | $199.32M | $221.04M | 10.90% | 08/08/2023 | |
HALO | Halozyme Therapeutics | $0.47 | $0.48 | $0.47 | -2.08% | $117.28M | $175.51M | $162.14M | -7.62% | 05/09/2023 | |
HALO | Halozyme Therapeutics | $0.42 | $0.47 | $0.48 | 2.13% | $102.00M | $192.05M | $181.50M | -5.50% | 02/21/2023 | |
HALO | Halozyme Therapeutics | $0.55 | $0.51 | $0.74 | 45.10% | $115.83M | $191.10M | $208.98M | 9.35% | 11/08/2022 | |
HALO | Halozyme Therapeutics | $0.66 | $0.50 | $0.53 | 6.00% | $136.46M | $138.78M | $152.37M | 9.79% | 08/09/2022 | |
HALO | Halozyme Therapeutics | $0.37 | $0.49 | $0.47 | -4.08% | $89.02M | $128.25M | $117.28M | -8.55% | 05/10/2022 | |
HALO | Halozyme Therapeutics | $0.50 | $0.41 | $0.42 | 2.44% | $121.70M | $100.32M | $102.00M | 1.68% | 02/22/2022 | |
HALO | Halozyme Therapeutics | $0.31 | $0.42 | $0.55 | 30.95% | $65.32M | $101.94M | $115.83M | 13.63% | 11/02/2021 | |
HALO | Halozyme Therapeutics | $0.19 | $0.40 | $0.66 | 65.00% | $55.22M | $103.16M | $136.46M | 32.28% | 08/09/2021 | |
HALO | Halozyme Therapeutics | -$0.04 | $0.32 | $0.37 | 15.62% | $25.35M | $84.88M | $89.02M | 4.88% | 05/10/2021 | |
HALO | Halozyme Therapeutics | -$0.24 | $0.53 | $0.50 | -5.66% | $53.66M | $120.16M | $121.70M | 1.28% | 02/23/2021 | |
HALO | Halozyme Therapeutics | -$0.17 | $0.20 | $0.25 | 25.00% | $46.23M | $60.91M | $65.32M | 7.23% | 11/02/2020 |
Halozyme Therapeutics (HALO) Guadagno per azione
Importo a sorpresa sugli utili trimestrali
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-05 | $1.54 | $1.20 | 28.3 % |
| Q1 | 2025-05-06 | $1.11 | $0.94 | 18.1 % |
| Q4 | 2025-02-18 | $1.26 | $1.16 | 8.62 % |
| Q3 | 2024-10-31 | $1.27 | $0.98 | 29.6 % |
Halozyme Therapeutics (HALO) Entrate
Importo sorpresa sulle entrate trimestrali
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-08-05 | $325.72M | $286.00M | 13.9 % |
| Q1 | 2025-05-06 | $264.86M | $230.18M | 15.1 % |
| Q4 | 2025-02-18 | $298.01M | $285.74M | 4.29 % |
| Q3 | 2024-10-31 | $290.08M | $251.06M | 15.5 % |
FAQ
Quando Halozyme Therapeutics (NASDAQ:HALO) riporterà gli utili?
Si prevede che Halozyme Therapeutics (HALO) fornisca risultati il ottobre 30, 2025. Gli ultimi risultati sono stati pubblicati il agosto 5, 2025 per il Q2.
Quali sono stati gli ultimi utili per azione (EPS) di Halozyme Therapeutics (NASDAQ:HALO)?
L'EPS effettivo era $1.54, che superato la stima di $1.20.
Quali sono state le entrate di Halozyme Therapeutics (NASDAQ:HALO)?
Le entrate effettive sono state $325.7M, che superato la stima di $286M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.